Latest News & Insights
Stay Up to Date with Our Community
Featured
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third...
Capsida is initiating the Phase 1/2 study for CAP-003, with the...
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance...
Capsida will also present data from its potential best-in-class programs for...
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration...
Neuron23 today announced the publication of a manuscript in the Proceedings of...
Data from the Phase 1 healthy volunteer study of NEU-411 will...
Financing led by funds managed by Blue Owl Capital; Senior Managing...
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in...
Capsida to receive a $40 million license payment and is eligible...